|Bid||11.51 x 1300|
|Ask||11.57 x 4000|
|Day's range||11.08 - 11.88|
|52-week range||4.34 - 24.55|
|Beta (5Y monthly)||-0.44|
|PE ratio (TTM)||N/A|
|Earnings date||30 Nov 2022 - 05 Dec 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||28 Apr 2014|
|1y target est||35.20|
In today's bearish market, consistent growth is hard to come by, but it still exists. With its shares up over 142% so far this year, it's a safe bet to call Veru (NASDAQ: VERU) a growth stock that's on a tear. The answer is that Veru is developing a treatment for severe COVID-19 called sabizabulin, and it's currently waiting on the final stamp of approval from regulators at the Food and Drug Administration (FDA).
Bear markets are often harrowing times to be invested in growth stocks, and this one's no exception. Between rising interest rates, inflation, and global disruption from the coronavirus, the shares of most growth-oriented companies have been hammered. With ShockWave Medical's (NASDAQ: SWAV) shares gaining 65.4% this year, it's safe to say that the bear market isn't causing it any problems.
Veru (NASDAQ: VERU), a high-flying cancer and COVID-19 stock, is in full-on retreat mode today. The good news is that Veru didn't release any material news today, so its value proposition hasn't suddenly changed. The bad news is that investors appear to be profit-taking across the varied healthcare landscape today in response to the Federal Reserve's plans to continue raising interest rates in 2023.